Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel/Cisplatin/Gemcitabine vs Cisplatin/Gemcitabine in Advanced Urothelial Cancer
NCT00022191Phase 3Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- May 2001
- Primary completion
- Jun 2004
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, open-label trial of paclitaxel in urothelial carcinoma (UC) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Overall Survival up to 5 years. Started May 2001; status: completed.
02
Drugs
paclitaxel
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT00022191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00022191.